EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS

Ammara Riaz Chohan, Asif Niaz, Farrukh Zara, Afsheen Ishfaq, Javeria Mehtab

BMC Journal of Medical Sciences · 29.06.2026 · 7 (1) · 82-86

DOI: 10.70905/bmcj.07.01.0641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Journal of Medical Sciences, online erschienen am 29.06.2026. Verfasst von Ammara Riaz Chohan und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes mellitus (T2DM) is a global health challenge associated with multiple significant complications. Recent studies suggest that use of dipeptidyl peptidase 4 (DPP-4) inhibitors, may be linked to acute cholecystitis and biliary dysfunction. Understanding this association is important, as biliary complications may adversely affect patient outcomes.

Objective

To explore the association between biliary disease, including acute cholecystitis, in patients with type 2 diabetes mellitus treated with DPP-4 inhibitors. Material and Methods: This cross-sectional study was conducted between Nov 2022 to August 2024 at PAF Hospital, Islamabad. The study population had two qual groups of 350 patients each comprising type 2 diabetic patients receiving DPP-4 inhibitors and those receiving other ant diabetic medications. The data regarding demographic characteristics and biliary outcomes were collected from their medical records using a structured questionnaire and analyzed using SPSS version 25 to find the association between biliary disease and use of DPP4 inhibitors.

Results

Patients receiving DPP-4 inhibitors showed a significantly higher frequency of acute cholecystitis compared to those receiving other antidiabetic medications (16.0% vs 10.0%, p=0.027; OR=1.71, 95% CI: 1.09–2.68). There were also higher frequencies of gallstones (22.0% vs 16.0%, p=0.153; OR=1.48, 95% CI: 0.99–2.20)and biliary sludge (24.0% vs 18.3%, p=0.076; OR=1.41, 95% CI: 0.97–2.05)in the DPP-4 inhibitor group; however, these differences were not statistically significant.

Conclusion

Our findings suggests an association between use of DPP-4 inhibitors and a higher frequency of acute cholecystitis and biliary disease in patients with type 2 diabetes mellitus, warranting careful monitoring in clinical practice.

Zitieren

APA

Chohan, A. R., Niaz, A., Zara, F., Ishfaq, A., & Mehtab, J. (2026). ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS. BMC Journal of Medical Sciences, 7(1), 82-86. https://doi.org/10.70905/bmcj.07.01.0641

Vancouver

Chohan AR, Niaz A, Zara F, Ishfaq A, Mehtab J. ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS. BMC Journal of Medical Sciences. 2026;7(1):82-86. doi:10.70905/bmcj.07.01.0641

BibTeX
@article{Chohan2026,
  author = {Chohan, Ammara Riaz and Niaz, Asif and Zara, Farrukh and Ishfaq, Afsheen and Mehtab, Javeria},
  title = {ASSOCIATION BETWEEN BILIARY DISEASE, INCLUDING ACUTE CHOLECYSTITIS,AND DIPEPTIDYL PEPTIDASE 4 INHIBITORS USE IN PATIENTS WITH TYPE 2 DIABETES MELITTUS},
  journal = {BMC Journal of Medical Sciences},
  year = {2026},
  volume = {7},
  number = {1},
  pages = {82--86},
  doi = {10.70905/bmcj.07.01.0641}
}
Kostenlos starten →